Are electronic investigator brochures legally binding?

Yes. Electronic investigator brochures executed with signer intent, consent, attribution, and reproducible records meet legal validity under the ESIGN Act (15 U.S.C. ch. 96) and state UETA statutes, except for transactions expressly excluded by statute; ensure consumer disclosures where applicable.

Does HIPAA affect e-signing investigator brochures?

Yes. When a brochure contains protected health information, HIPAA requires administrative, physical, and technical safeguards and a Business Associate Agreement with vendors handling PHI; retain records for six years per 45 CFR §164.530(j) and follow institutional policies.

Is notarization or RON required?

Notarization requirements vary by state and by document content. Investigator brochures rarely require notarization; if signatures require notarization use RON where permitted with identity proofing, audio-video recording, and retention per state rules.

How should I save and export the brochure?

Export signed brochures as tamper-evident PDF/A with embedded audit trail where possible. Store encrypted copies with access controls and backup. Maintain version-controlled originals and retain export metadata to support reproductions during regulatory inspections.

What constitutes a valid electronic signature?

A valid e-signature shows signer intent, consent to electronic records, clear attribution, and retained reproducible records. For consumer-facing transactions provide ESIGN consumer disclosures and methods to withdraw consent when required by 15 U.S.C. §7001(c).

Can I use signNow to sign and store this brochure?

signNow supports HIPAA workflows with a BAA option, encrypts data (TLS in transit, AES-256 at rest), and holds SOC 2 Type II and ISO 27001 certifications. Plans start at $8/user/month and a 7-day free trial is available; confirm institutional BAA needs.

Electronic Signature
Templates
Healthcare
Healthcare Investigator Brochure

Healthcare Investigator Brochure

This template is fully customizable. Edit the text, fill out the fields, and send it for signature. Give it a try!

HEALTHCARE INVESTIGATOR BROCHURE

Sponsor Name:

Protocol Title:

Investigational Product (INN / Code): IB Version:

IB Date:

Sponsor Contact for Medical Questions: Phone:

CONFIDENTIALITY

This Investigator Brochure contains confidential information proprietary to the Sponsor. The Investigator agrees to maintain confidentiality of investigational product information, preclinical and clinical data contained herein and to disclose such information only to authorized personnel who are subject to confidentiality obligations. Use of the information is limited to management and conduct of the protocol identified above.

1. SUMMARY OF THE INVESTIGATIONAL PRODUCT

Concise Summary (clinical and nonclinical highlights):

2. BACKGROUND AND RATIONALE

Background, mechanism of action, and scientific rationale for the proposed clinical investigation:

3. INVESTIGATOR RESPONSIBILITIES

The Investigator is responsible for conduct of the study consistent with the protocol, applicable regulations, and IRB/IEC requirements. The Investigator shall ensure informed consent is obtained and documented for each subject and shall maintain accurate source documentation and regulatory records.

Investigator Name Institution / Facility IRB / Ethics Committee Contact

Confirmation of responsibilities:

Investigator will obtain written informed consent from each subject prior to any study-specific procedures.

Investigator will retain study records and source documents as required by applicable regulation and Sponsor policy.

4. INVESTIGATIONAL PRODUCT DESCRIPTION, HANDLING, AND DOSING

Pharmaceutical description, formulation, primary storage conditions and precautions:

Storage Conditions Dosing Regimen / Administration Accountability and Returns

5. KNOWN AND POTENTIAL RISKS

Known adverse events, laboratory abnormalities, and potential risks based on available data:

6. ADVERSE EVENT REPORTING

Reporting obligations for adverse events, including Serious Adverse Events (SAEs), unexpected serious suspected adverse reactions (SUSARs) and timelines for notification to Sponsor and regulatory authorities.

SAE Contact — Name SAE Contact — Phone SAE Contact — Email

The Investigator shall notify the Sponsor of any SAE within 24 hours of becoming aware and shall submit complete SAE reports as required by Sponsor and applicable regulations.

7. MONITORING, AUDITS, AND RECORDS

Monitoring plan, frequency of site visits, audit access and responsibilities related to source data verification and protocol compliance.

Record Retention Period

8. DATA HANDLING AND CONFIDENTIALITY

Data collection, handling, coding of subject identifiers, and measures to protect confidentiality of subject health information. Investigators must comply with applicable privacy laws and institutional policies.

Investigator affirms that subject identifiers will be maintained securely, access to identifiable information will be limited to authorized personnel, and data transfers will be performed in accordance with Sponsor guidance and applicable regulation.

9. REFERENCES AND APPENDICES

References, investigator contact list, sample informed consent form, pharmacy instructions, and other appendices are attachments to this Investigator Brochure.

ACKNOWLEDGMENT

By signing below, the Investigator acknowledges receipt of this Investigator Brochure, confirms that they have read and understand the contents, and agrees to conduct the study in accordance with the protocol, applicable regulations, IRB/IEC requirements and Sponsor instructions. The Investigator agrees to promptly notify the Sponsor of any new safety information or protocol deviations.

I acknowledge receipt of this Investigator Brochure and accept the responsibilities described herein.

Investigator Name:

Signature:

Date:

What the Healthcare Investigator Brochure Is

The Healthcare Investigator Brochure is a structured document used by clinical research monitors, quality assurance teams, and regulatory investigators to summarize study design, participant protections, investigational product details, and data collection methods. It consolidates protocol highlights, safety monitoring plans, regulatory approvals, and contact information so investigators and oversight bodies can evaluate compliance and risk efficiently. In U.S. clinical settings this brochure supports inspections, corrective action planning, and institutional review board communications while helping ensure alignment with Good Clinical Practice and applicable federal rules governing patient privacy and records.

Why a Clear Investigator Brochure Matters

Provides a concise, auditable summary that expedites investigator review, clarifies safety responsibilities, and documents regulatory decisions. For U.S. healthcare and research organizations it supports HIPAA-compliant handling of protected health information and regulatory oversight under FDA and institutional review frameworks.

Who Typically Prepares and Uses This Brochure

Clinical investigators, sponsor QA teams, IRB staff, and institutional compliance officers commonly use this brochure during study reviews.

Principal investigators and subinvestigators responsible for conduct and reporting of clinical studies.
Sponsor quality assurance and pharmacovigilance teams reviewing safety and compliance records.
IRB administrators and regulatory affairs staff assessing protocol adherence and participant protections.

Smaller research sites and CROs also prepare investigator brochures to standardize records and support audits or inspections.

Step-by-Step Checklist to Prepare the Brochure

Follow this sequential checklist to prepare and finalize the Healthcare Investigator Brochure for regulatory and internal review.

01

Gather Documents: Collect protocol, informed consent forms, safety reports.
02

Draft Summary: Write protocol overview, objectives, and methodology concisely.
03

Assemble Safety: Compile AE summaries, monitoring plans, and SAE logs.
04

Review & Sign: Route for QA and investigator signatures with dates.

Recommended Digital Workflow Settings

Recommended digital workflow settings for securely completing and distributing the Healthcare Investigator Brochure electronically.

Field	Configuration
Authentication	Email link plus optional SMS code
Document Format	PDF/A format with embedded form fields
Signature Type	Audit-trail e-signature with server timestamp
Retention	Store encrypted PDF for minimum six years

Typical eSubmission and Routing Flow

Basic routing and eSubmission flow used when sharing the brochure electronically with stakeholders for review.

Upload Document: Save PDF and upload to your e-signature platform.
Place Fields: Insert signature, date, and initials fields.
Add Signers: Enter signer emails and role order.
Send & Track: Issue signing link, monitor status, and download certificate.

Platform Capabilities to Look For

Platform requirements for e-submission and secure sharing of the Healthcare Investigator Brochure with audit trails.

File Types: PDF, DOCX, or HTML accepted
Integrations: Salesforce, NetSuite, Google Workspace
Security: AES-256 at rest, TLS in transit

Core Sections to Include in a Professional Brochure

Core sections commonly included in a professional Healthcare Investigator Brochure to meet regulatory, safety reporting, and operational oversight needs across sites.

Protocol Summary

Concise synopsis of study objectives, design, inclusion/exclusion criteria, primary and secondary endpoints, randomization schema, and key procedures. Use language consistent with the approved protocol to avoid discrepancies during review.

Safety Data

Aggregated adverse event summaries, serious adverse event line listings, investigator causality assessments, and cumulative safety analyses. Include time frames, denominators, and thresholds that trigger expedited reporting to regulators or sponsors.

Investigator Responsibilities

Clear statement of investigator duties including informed consent oversight, source data verification, reporting obligations for unanticipated problems, and adherence to protocol deviations procedures required by IRBs and sponsors.

Monitoring Plan

Schedule of monitoring visits, targeted data queries, centralized review activities, escalation paths for findings, and criteria for on-site follow-up or audit, including responsible parties and timelines.

Contact Information

Complete contact list for sponsor medical monitor, safety officer, study coordinator, IRB contact, and emergency clinical liaison. Include 24/7 escalation numbers and secure email addresses where required.

Amendments Log

Chronological record of protocol amendments, brochure revisions, approval dates, and effective dates. Note which sites received each update and maintain version-controlled copies for inspection and confirmation receipts.

Security and Compliance Essentials

Encryption: TLS 1.2/1.3 in transit; AES-256 at rest

Certifications: SOC 2 Type II, ISO 27001, PCI DSS

HIPAA: BAA required for PHI handling

21 CFR Part 11: Compliant controls available for FDA records

ESIGN / UETA: Electronic signatures legally binding in U.S.

Audit Trail: Detailed timestamps, IP, and signer history

Common Preparation Mistakes to Avoid

Using inconsistent protocol titles or version numbers that create confusion during audits and can delay IRB or sponsor approvals.
Failing to include complete safety line listings or denominator data, which impedes aggregate safety assessments and regulatory reporting.
Omitting contact escalation numbers or emergency contacts, resulting in delayed response to serious adverse events or queries.
Uploading non-searchable scanned PDFs without embedded fields, causing routing errors, missed fields, and longer completion times.

Consequences of Inaccurate or Incomplete Brochures

Regulatory Findings: FDA inspectional observations

HIPAA Violations: Civil penalties and corrective plans

Data Integrity Issues: Study validity at risk

Delayed Reporting: Late safety submissions penalized

Credibility Loss: Sponsor or site reputation harmed

Audit Costs: Remediation and legal expense

Key Timelines and Deadlines

Key timelines and deadlines for drafting, review, and submission of the Healthcare Investigator Brochure to regulatory bodies.

Draft Completion:

Target within 30 days of protocol finalization.

Internal Review:

Allow fourteen to twenty-one days for QA and sponsor review.

IRB Submission:

Submit concurrently with informed consent materials.

Amendment Filing:

File updates within 30 days of substantive change.

Retention Start:

Retention begins on effective date of the document.

Pricing and Feature Snapshot for eSignature Vendors

High-level pricing and feature comparison for eSignature vendors commonly used to sign investigator brochures in clinical and healthcare settings.

	signNow	DocuSign	Adobe Sign	PandaDoc	HelloSign
Starting Price	$8/user/mo	$15/user/mo	$14/user/mo	$19/user/mo	$15/user/mo
Free Trial	7-day trial	Varies	Varies	Varies	Varies
Bulk Send	Yes	Yes	Yes	Yes	No
Audit Trail	Yes	Yes	Yes	Yes	Yes
HIPAA Compliant	Yes	Yes	Yes	No	No
Envelope Cap	No cap	100 envelopes/user/year	Varies by plan	Varies by plan	Varies by plan

Frequently Asked Questions and Troubleshooting

[INTRO] Common questions about legal validity, e-signing, storage, and platform compatibility when handling the Healthcare Investigator Brochure electronically.

Need help? Contact support

Are electronic investigator brochures legally binding?
Yes. Electronic investigator brochures executed with signer intent, consent, attribution, and reproducible records meet legal validity under the ESIGN Act (15 U.S.C. ch. 96) and state UETA statutes, except for transactions expressly excluded by statute; ensure consumer disclosures where applicable.
Does HIPAA affect e-signing investigator brochures?
Yes. When a brochure contains protected health information, HIPAA requires administrative, physical, and technical safeguards and a Business Associate Agreement with vendors handling PHI; retain records for six years per 45 CFR §164.530(j) and follow institutional policies.
Is notarization or RON required?
Notarization requirements vary by state and by document content. Investigator brochures rarely require notarization; if signatures require notarization use RON where permitted with identity proofing, audio-video recording, and retention per state rules.
How should I save and export the brochure?
Export signed brochures as tamper-evident PDF/A with embedded audit trail where possible. Store encrypted copies with access controls and backup. Maintain version-controlled originals and retain export metadata to support reproductions during regulatory inspections.
What constitutes a valid electronic signature?
A valid e-signature shows signer intent, consent to electronic records, clear attribution, and retained reproducible records. For consumer-facing transactions provide ESIGN consumer disclosures and methods to withdraw consent when required by 15 U.S.C. §7001(c).
Can I use signNow to sign and store this brochure?
signNow supports HIPAA workflows with a BAA option, encrypts data (TLS in transit, AES-256 at rest), and holds SOC 2 Type II and ISO 27001 certifications. Plans start at $8/user/month and a 7-day free trial is available; confirm institutional BAA needs.

be ready to get more

Join over 28 million airSlate SignNow users

Sign Now